The role of vitamin D in CKD stages 3 to 4: report of a scientific workshop sponsored by the National Kidney Foundation

ML Melamed, M Chonchol, OM Gutiérrez… - American journal of …, 2018 - Elsevier
Deficiency of 25-hydroxyvitamin D (25 [OH] D) is common in patients with chronic kidney
disease stages 3 and 4 and is associated with poor outcomes. However, the evaluation and …

Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients

W Sutton, X Chen, P Patel, S Karzai, JD Prescott… - Surgery, 2022 - Elsevier
Background Tertiary hyperparathyroidism after kidney transplantation has been associated
with graft dysfunction, cardiovascular morbidity, and osteopenia; however, its true …

Secondary hyperparathyroidism (CKD-MBD) treatment and the risk of dementia

A Mathur, JYB Ahn, W Sutton, NM Chu… - Nephrology Dialysis …, 2022 - academic.oup.com
Background Elevated parathyroid hormone (PTH) levels have been reported as a potential
risk factor for cognitive impairment. Compared with the general population, older adults with …

Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients

K Kalantar‐Zadeh, JE Miller, CP Kovesdy… - Journal of Bone and …, 2010 - academic.oup.com
Blacks have high rates of chronic kidney disease, are overrepresented among the US
dialysis patients, have higher parathyroid hormone levels, but greater survival compared to …

[PDF][PDF] Incorporation of Calcimimetics into ESRD Bundle: Changes in Etelcalcetide Utilization and PTH Control Following End of TDAPA Designation

A Karaboyas, J Zhao, J Ma, C Moore… - Clinical Journal of the …, 2024 - journals.lww.com
Methods: This analysis included 713 US in-center hemodialysis patients enrolled in the
United States Dialysis Outcomes and Practice Patterns Study (US-DOPPS) who …

[HTML][HTML] Mineral and bone disease in black african hemodialysis patients: a report from senegal

SM Seck, M Dahaba, EF Ka, MM Cisse… - Nephro-urology …, 2012 - ncbi.nlm.nih.gov
Mineral and Bone Disease in Black African Hemodialysis Patients: A Report From Senegal -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Variability in cinacalcet prescription across US hemodialysis facilities

DS Fuller, S Xing, V Belozeroff… - Clinical Journal of the …, 2019 - journals.lww.com
Results The mean percentage of patients in each facility with cinacalcet prescription was
23% in June 2014 (median, 22%; interquartile range, 13%–30%). Adjusted for facility-level …

Reducing disparities in the treatment of hyperparathyroidism

A Gillis, R Wang, PV Zmijewski, MC McLeod… - Heliyon, 2024 - cell.com
Background Hyperparathyroidism is common with African American patients historically
experiencing disparate outcomes. With a comprehensive outreach program and systematic …

[HTML][HTML] Incorporation of Calcimimetics into End-Stage Kidney Disease Bundle: Changes in Etelcalcetide Utilization and Parathyroid Hormone Control following End of …

A Karaboyas, J Zhao, J Ma, C Moore… - Clinical Journal of the …, 2024 - journals.lww.com
Background Calcimimetics, including intravenous etelcalcetide and oral cinacalcet, are often
prescribed to hemodialysis patients to prevent complications of elevated parathyroid …

Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis

M Laster, M Soohoo, E Streja, R Elashoff… - Pediatric …, 2019 - Springer
Background Studies in healthy pediatric populations and adults treated with dialysis
demonstrate higher parathyroid hormone (PTH) and lower 25-hydroxyvitamin D levels in …